R&D News | pharmaphorum

News

Cardurion heads crop of sizeable bio financings

While the pace of biotech private rounds seems to have slowed a little of late, this week saw four big financings for Cardurion Pharma, Scorpion Therapeutics, CatalYm, and NGM Bio.

News

Re-elected von der Leyen pledges EU measures for biotech

Ursula von der Leyen has been re-elected as president of the European Commission following a secret ballot in the European Parliament and, among the pledges made during her speech before th

News

Merdad Parsey will leave Gilead next year

Gilead Sciences' chief medical officer, Merdad Parsey, will leave the company in early 2025, becoming the latest in a series of high-profile departures involving senior R&D figures at t

News

Trial sets up wider use of Bayer's Nubeqa in prostate cancer

Bayer has the result it was hoping for in the phase 3 ARANOTE trial of Nubeqa in metastatic, hormone-sensitive prostate cancer (mHSPC), a key part of its plan to build the drug into a €3 bi

News

Roche reveals first data with Carmot-sourced oral GLP-1 drug

Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of its $3.1 billion takeover of Carmot Therapeutics as it tries to catch up with the leaders in the

News

Vertex, Orum partner on safer pre-treatment for gene meds

Vertex Pharma has teamed up with Orum Therapeutics to develop a conditioning regimen, used to prepare patients to receive gene-editing medicines, that it hopes will offer a more tolerable a

Cardurion heads crop of sizeable bio financings

Re-elected von der Leyen pledges EU measures for biotech

Merdad Parsey will leave Gilead next year

Trial sets up wider use of Bayer's Nubeqa in prostate cancer

Roche reveals first data with Carmot-sourced oral GLP-1 drug

Vertex, Orum partner on safer pre-treatment for gene meds

Novartis CEO joins board of "responsible" AI firm Anthropic

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks